Roth/MKM Downgrades LB Pharmaceuticals Inc (LBRX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts LBRX Hot Sheet
Price: $39.31 +1.50%
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 40
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 40
Join SI Premium – FREE
Roth/MKM analyst Boobalan Pachaiyappan downgraded LB Pharmaceuticals Inc (NASDAQ: LBRX) from Buy to Neutral.
For an analyst ratings summary and ratings history on LB Pharmaceuticals Inc click here. For more ratings news on LB Pharmaceuticals Inc click here.
Shares of LB Pharmaceuticals Inc closed at $36.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Iran Ready To Back 'Any Understanding' For Regional Unity - IRIB
- Sonoco Products (SON) PT Lowered to $50 at UBS on Inflation, Weak Volumes
- Comfort Systems USA (FIX) PT Lowered to $1,850 at DA Davidson, 2027 Estimates Raised
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
